Payment overview · 2025
General Payments
$1,347.80
78 reported records · 25 companies
Healthcare provider profile · identity verified
Shane D Gagon, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PRICE, UT · NPI 1508951328
Verified facts
What the public records show
CMS Open Payments records show Shane D Gagon, M.D. received $1,347.80 in general payments during 2025 across 78 reported records.
ABBVIE INC. accounted for 19.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $257.70 | 19.1% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $246.81 | 18.3% | 14 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $146.92 | 10.9% | 16 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $96.19 | 7.1% | 5 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $80.69 | 6.0% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $65.55 | 4.9% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $60.72 | 4.5% | 3 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $46.92 | 3.5% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $35.84 | 2.7% | 2 | 2025 |
| PROTEGA PHARMACEUTIALS INC | Unresolved — no canonical attribution shown | $29.50 | 2.2% | 2 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $25.86 | 1.9% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $25.70 | 1.9% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $23.02 | 1.7% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.02 | 1.5% | 1 | 2025 |
| C2N Diagnostics, LLC | Unresolved — no canonical attribution shown | $19.88 | 1.5% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $19.28 | 1.4% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $19.22 | 1.4% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $17.82 | 1.3% | 1 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $17.20 | 1.3% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$16.94 | 1.3% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.70 | 1.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.62 | 1.2% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $15.42 | 1.1% | 1 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.40 | 1.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $13.88 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,347.80 | 78 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $140.91 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $116.79 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $116.79 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $112.02 | 14 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $112.02 | 14 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $102.46 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $96.19 | 5 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $80.69 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $79.48 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $65.55 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $64.87 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $60.72 | 3 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $46.92 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $35.84 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $35.84 | 2 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $35.84 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $34.90 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $34.90 | 2 | 2025 |
Source payment records
|
|||||
| ROXYBOND Normalized: roxybond |
Drug | PROTEGA PHARMACEUTIALS INC | $29.50 | 2 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $25.86 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $25.70 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $23.02 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $20.06 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| PRECIVITYAD2 Normalized: precivityad2 |
Device | C2N Diagnostics, LLC | $19.88 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $19.28 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $19.28 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $18.06 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $17.82 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $17.20 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $16.94 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $15.70 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.62 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $15.42 | 1 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $14.84 | 1 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $14.84 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 83 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 111 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 133 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
85 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
111 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
133 | 25 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
83 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
83 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1002 | 277 |
| Levothyroxine Sodium | Levothyroxine Sodium | 733 | 192 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 685 | 217 |
| Losartan Potassium | Losartan Potassium | 610 | 190 |
| Gabapentin | Gabapentin | 589 | 115 |
| Omeprazole | Omeprazole | 513 | 140 |
| Pantoprazole Sodium | Pantoprazole Sodium | 466 | 135 |
| Oxycodone Hcl | Oxycodone Hcl | 430 | 53 |
| Lisinopril | Lisinopril | 423 | 135 |
| Metoprolol Succinate | Metoprolol Succinate | 410 | 129 |
| Tramadol Hcl | Tramadol Hcl | 386 | 88 |
| Metformin Hcl | Metformin Hcl | 326 | 97 |
| Amlodipine Besylate | Amlodipine Besylate | 316 | 109 |
| Trazodone Hcl | Trazodone Hcl | 307 | 90 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 298 | 81 |
| Carvedilol | Carvedilol | 272 | 84 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 256 | 61 |
| Potassium Chloride | Potassium Chloride | 236 | 66 |
| Simvastatin | Simvastatin | 234 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 233 | 70 |
| Meloxicam | Meloxicam | 225 | 70 |
| Furosemide | Furosemide | 221 | 62 |
| Alendronate Sodium | Alendronate Sodium | 216 | 83 |
| Pregabalin | Pregabalin | 208 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 207 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 205 | 55 |
| Doxycycline Hyclate | Doxycycline Hyclate | 187 | 126 |
| Fluoxetine Hcl | Fluoxetine Hcl | 184 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 174 | 53 |
| Montelukast Sodium | Montelukast Sodium | 171 | 46 |
| Allopurinol | Allopurinol | 168 | 47 |
| Zolpidem Tartrate | Zolpidem Tartrate | 166 | 23 |
| Donepezil Hcl | Donepezil Hcl | 163 | 42 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 155 | 51 |
| Metformin Hcl Er | Metformin Hcl | 148 | 47 |
| Celecoxib | Celecoxib | 144 | 43 |
| Lorazepam | Lorazepam | 137 | 21 |
| Sertraline Hcl | Sertraline Hcl | 137 | 49 |
| Spironolactone | Spironolactone | 136 | 41 |
| Methylprednisolone | Methylprednisolone | 135 | 100 |
| Ondansetron Hcl | Ondansetron Hcl | 134 | 47 |
| Jardiance | Empagliflozin | 133 | 25 |
| Chlorthalidone | Chlorthalidone | 132 | 53 |
| Fluticasone Propionate | Fluticasone Propionate | 121 | 45 |
| Oxybutynin Chloride | Oxybutynin Chloride | 121 | 36 |
| Ozempic | Semaglutide | 120 | 29 |
| Levetiracetam | Levetiracetam | 119 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 119 | 29 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 116 | 23 |
| Farxiga | Dapagliflozin Propanediol | 111 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 110 | 39 |
| Ezetimibe | Ezetimibe | 110 | 37 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 110 | 42 |
| Alprazolam | Alprazolam | 103 | 21 |
| Xarelto | Rivaroxaban | 103 | 25 |
| Famotidine | Famotidine | 101 | 37 |
| Bupropion Xl | Bupropion Hcl | 100 | 35 |
| Glimepiride | Glimepiride | 100 | 32 |
| Quetiapine Fumarate | Quetiapine Fumarate | 100 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 98 | 25 |
| Methocarbamol | Methocarbamol | 98 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 97 | 30 |
| Myrbetriq | Mirabegron | 97 | 21 |
| Ibuprofen | Ibuprofen | 96 | 33 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 95 | 11 |
| Torsemide | Torsemide | 95 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 94 | 31 |
| Ropinirole Hcl | Ropinirole Hcl | 93 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 92 | 16 |
| Warfarin Sodium | Warfarin Sodium | 92 | 21 |
| Azithromycin | Azithromycin | 88 | 43 |
| Cefdinir | Cefdinir | 86 | 62 |
| Synthroid | Levothyroxine Sodium | 85 | 27 |
| Clonazepam | Clonazepam | 83 | 13 |
| Eliquis | Apixaban | 83 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 83 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 83 | 47 |
| Diclofenac Sodium | Diclofenac Sodium | 82 | 26 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 81 | 64 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 78 | 23 |
| Memantine Hcl | Memantine Hcl | 77 | 21 |
| Baclofen | Baclofen | 74 | 15 |
| Prednisone | Prednisone | 74 | 49 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 73 | 19 |
| Mirtazapine | Mirtazapine | 73 | 22 |
| Testosterone Cypionate | Testosterone Cypionate | 72 | 14 |
| Divalproex Sodium | Divalproex Sodium | 71 | 15 |
| Fentanyl | Fentanyl | 70 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 69 | 29 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 69 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 68 | 46 |
| Promethazine Hcl | Promethazine Hcl | 68 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 66 | 19 |
| Estradiol | Estradiol | 62 | 25 |
| Morphine Sulfate Er | Morphine Sulfate | 62 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 62 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 59 | 16 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 57 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 53 | 13 |
| Finasteride | Finasteride | 52 | 12 |
| Sucralfate | Sucralfate | 52 | 13 |
| Irbesartan | Irbesartan | 50 | 19 |
| Primidone | Primidone | 50 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | 15 |
| Ondansetron Odt | Ondansetron | 48 | 27 |
| Valsartan | Valsartan | 48 | 11 |
| Topiramate | Topiramate | 47 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 46 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 46 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 44 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 44 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 44 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | 11 |
| Raloxifene Hcl | Raloxifene Hcl | 41 | 11 |
| Amoxicillin | Amoxicillin | 40 | 32 |
| Methotrexate | Methotrexate Sodium | 40 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 39 | 11 |
| Propranolol Hcl | Propranolol Hcl | 39 | 16 |
| Bumetanide | Bumetanide | 38 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 38 | 12 |
| Aripiprazole | Aripiprazole | 37 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 37 | 12 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 36 | suppressed |
| Fluconazole | Fluconazole | 35 | 22 |
| Memantine Hcl Er | Memantine Hcl | 35 | suppressed |
| Novolog Flexpen | Insulin Aspart | 35 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 35 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 34 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Olanzapine | Olanzapine | 33 | suppressed |
| Diazepam | Diazepam | 32 | 11 |
| Doxepin Hcl | Doxepin Hcl | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Errin | Norethindrone | 31 | suppressed |
| Nystatin | Nystatin | 31 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 29 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Belsomra | Suvorexant | 28 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | 15 |
| Lansoprazole | Lansoprazole | 27 | suppressed |
| Linzess | Linaclotide | 27 | suppressed |
| Movantik | Naloxegol Oxalate | 27 | suppressed |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 25 | 13 |
| Levofloxacin | Levofloxacin | 25 | 23 |
| Metolazone | Metolazone | 25 | suppressed |
| Amantadine | Amantadine Hcl | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 24 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Metronidazole | Metronidazole | 21 | 19 |
| Sotalol | Sotalol Hcl | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 19 | 19 |
| Dutasteride | Dutasteride | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Paliperidone Er | Paliperidone | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Carbamazepine Er | Carbamazepine | 17 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | 15 |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 16 | suppressed |
| Novolin R | Insulin Regular, Human | 16 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Ertapenem | Ertapenem Sodium | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Repatha Syringe | Evolocumab | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Dexamethasone | Dexamethasone | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 13 | suppressed |
| Oxymorphone Hcl Er | Oxymorphone Hcl | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Praluent Pen | Alirocumab | 13 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Dilantin | Phenytoin | 12 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 12 | suppressed |
| Ramelteon | Ramelteon | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Droplet Insulin Syringe | Syrge-Ndl,ins 0.5 Ml Half Mark | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,347.80 · 78 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, BEYFORTUS, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, ELIQUIS, ENFLONSIA, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, GARDASIL 9, GEMTESA, INGREZZA, JARDIANCE, JOURNAVX, KEVEYIS, Kerendia, MINIMED 780G, Motpoly XR, NURTEC ODT, Ohtuvayre, PENBRAYA, PRECIVITYAD2, PREVNAR 20, QULIPTA, Qelbree, REXULTI, ROXYBOND, SKYCLARYS, Senza, TRUMENBA, TZIELD, UBRELVY, VAXELIS, VAXNEUVANCE, VRAYLAR, WAKIX, XIFAXAN, ZAVZPRET | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error